ClinicalTrials.gg
CompletedNCT06732466CHX TPUpdated Aug 6, 2025

Evaluation of the Effect of a Toothpaste Containing 0.3% Chlorhexidine in Subjects With Established Dental Plaque and Gingivitis

A Phase 3 interventional study of Chlorhexidine toothpaste and Toothbrush in Gingivitis, Gingivitis and Periodontal Diseases and Gingival Disease, sponsored by Colgate Palmolive. Completed at 1 site in Brazil. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by Colgate Palmolive · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 44 studies in Gingivitis by Colgate Palmolive — 8 open to participants now, 9 under way, 5 of them phase 3. Gingivitis · Colgate Palmolive.

Enrollment
34th of 44
80 · median 94
Started
2025
with 5 others
Phase 3
25 of 44
4 open now
Registered
26th of 44
by date

Among the 44 studies in Gingivitis by Colgate Palmolive, this one is the 34th largest by enrollment, is one of 6 that started in 2025, is one of 25 in phase 3, and was the 26th registered.

Gingivitis

634 studies on the registry are indexed under Gingivitis; 109 are open to participants now.

Browse Gingivitis studies →

Open to participants now

8 of the 44 studies in Gingivitis by Colgate Palmolive are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 54 Gingivitis studies recruiting now, 16 (30%) set no upper age limit and 36 (67%) stop at 75 or younger; 11 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Gingivitis by Colgate Palmolive, or all of them as a file.
02

Study summary

This is a Phase III, one-center, parallel group, double blind, clinical study to evaluate the effect of a toothpaste containing 0.3% chlorhexidine in subjects with established dental plaque and gingivitis. It involves 80 participants aged between 18 and 70, randomly assigned to different groups, and spans 21 days.

Read the detailed description

This clinical study aims to evaluate the effect of a toothpaste containing 0.3% chlorhexidine in subjects with established dental plaque and gingivitis. It is a Phase III study designed as randomized, one-center, double blind, parallel group trial involving 80 participants aged 18 to 70. Subjects will be divided into two groups: test group - subjects assigned to use a toothpaste with a 0.3% chlorhexidine + 3% AmCl and brush with a commercially available adult soft bristle toothbrush; negative control group - subjects assigned to use a placebo toothpaste without chlorhexidine and AmCl and brush with a commercially available adult soft bristle toothbrush. Subjects will undergo baseline, 14 days and 21 days evaluations. The primary outcome will be reduction of gingival inflammation and data will be analyzed using ANCOVA to assess the efficacy of the test product. Adverse events and compliance will be closely monitored, with strict confidentiality maintained for all participants. The study rigorous design aims to provide comprehensive insights into the effectiveness of the chlorhexidine toothpaste regarding gingivitis and dental plaque control.

03

Conditions studied

  • Gingivitis
  • Gingivitis and Periodontal Diseases
  • Gingival Disease
  • Dental Plaque

Keywords

  • chlorhexidine
  • toothpastes
  • gingivitis
  • dental plaque
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females, between 18-70 years of age;
  • Availability for the duration of the study;
  • Good general health (absence of any condition that, in the opinion of the Principal Investigator, might constitute a risk to the subject while participating in the study. Examples include heart problems, valve/hip replacements, etc);
  • Willingness to provide information related to their medical history;
  • Minimum of 20 uncrowned permanent natural teeth (excluding third molars and crowns);
  • Initial gingivitis index a minimum average score of 1.5 as determined by the use of the Löe and Silness Gingival Index;
  • More than 30% of bleeding sites and absence of periodontal disease;
  • Form signed.

Exclusion criteria

Exclusion Criteria:

  • Absence of visible clinical signs of periodontal disease, such as the presence of suppuration, dental mobility, and/or extensive attachment loss;
  • That received dental prophylaxis within 1 month prior to the Baseline visit;
  • Oral pathology or a history of allergy to testing products;
  • Subject using anticonvulsants, antihistamines, antidepressants, sedatives, tranquilizers, anti-inflammatory medication or daily analgesics within one month prior to the start of the study or scheduled to start such intake during the course of the study; to be defined by the dental examiner;
  • Subject participating in any other clinical study;
  • Subject pregnant or breastfeeding;
  • Subject allergic to oral care products, personal care consumer products, or their ingredients;
  • Extended use of antibiotics or therapeutic mouthwash (eg: Chlorhexidine) any time during the three months prior to entry into the study;
  • Ongoing use of medications known to affect the gingival tissues (i.e. calcium channel blockers, phenytoin, cyclosporine);
  • Current smokers and subjects with a history of alcohol or drug abuse;
  • Subjects with orthodontic appliances or presence of fixed or removable prosthodontics dentures that may interfere with the evaluations
  • An existing medical condition (eg: diabetic people) which prohibits eating or drinking for periods up to 4 hours.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    0.3% chlorhexidine toothpaste

    Test group assigned to use a 0.3% chlorhexidine + 3% AmCl toothpaste and brushing with a commercially available adult soft bristle toothbrush

    Drug: Chlorhexidine toothpaste · Device: Toothbrush

  • Placebo comparator
    Negative Control

    Negative Control group assigned to use a placebo toothpaste without chlorhexidine and AmCl and brushing with a commercially available adult soft bristle toothbrush

    Device: Toothbrush · Drug: Placebo toothpaste without chlorhexidine and AmCl

Interventions

  • DrugChlorhexidine toothpaste

    A toothpaste containing 0.3% chlorhexidine + 3% AmCl

  • DeviceToothbrush

    Commercially available adult soft bristle toothbrush

  • DrugPlacebo toothpaste without chlorhexidine and AmCl

    Negative Control Group assigned to use a placebo toothpaste without chlorhexidine and AmCl and brushing with a commercially available adult soft bristle toothbrush.

06

What researchers measure

Primary outcomes

  1. Löe-Silness Gingival Index

    A Löe-Silness Gingival Index score from 0 to 3 will be assigned by the examining dentist to all scorable surfaces of the maxillary and mandibular teeth using a dental light and dental mirror. A whole mouth mean score for each subject will be determined by adding the values given by the examining dentist to each scorable surface and dividing that number by the total number of surfaces scored.

    Time frame: 21 days

Secondary outcomes

  1. Modified Quigley-Hein Plaque Index

    The Turesky modification of the Quigley-Hein Plaque Index is a method for assessing dental plaque accumulation by scoring plaque presence on six surfaces of each tooth on a scale from 0 to 5.

    Time frame: 21 days

  2. Lobene Stain index

    The labial/lingual surface of each tooth will be divided into two regions: the gingival region, and the body region. The gingival and body regions would be scored separately for yellow stains by use criteria for intensity or severity: 0- no stain, 1- light stain, 2-moderate stain, and 3-heavy stain. The extent to which these yellow stains covered the gingival and body regions will be scored: 0-no stain detected, only tooth color, 1- stain covering up to 1/3 of the region, 2- stain covering from 1/3 to 2/3 of the region, and 3- stain over two thirds of the region. The sum of the stain scores for a subject will be used as that subject's stain score.

    Time frame: 21 days

07

Study locations

1 site
  • Federal University of Rio Grande do Sul
    Porto Alegre, Rio Grande do Sul, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Apr 2025, 0 months.

Of 23 industry-sponsored phase 3 interventional studies under Gingivitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 6. This study's 0 months is below that.

Counting every sponsor, half of 35 studies reached it within 3 months; a quarter within 2 and three quarters within 6.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Dec 13, 2024
StartActual
Mar 24, 2025
Primary completionActual
Apr 15, 2025
CompletionActual
Apr 15, 2025
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06732466
Lead sponsor
Colgate Palmolive
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Mar 24, 2025
Primary completion
Apr 15, 2025
Completion
Apr 15, 2025
Last update
Aug 6, 2025

Study contacts

Cassiano K Rosing, PhD
principal investigator · Federal University of Rio Grande do Sul

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion